Related Experiment Video

Updated: Mar 5, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme

Dorota Lubanska1, Lisa Porter2

  • 1Department of Biological Sciences, University of Windsor, 401 Sunset Ave, Biology rm. 201, Windsor, ON, N9B 3P4, Canada.

Drugs in R&D
|March 22, 2017
PubMed

Insights

Targeting cyclin-dependent kinases (CDKs) in glioblastoma stem cells may overcome treatment resistance. This approach, informed by cancer stem cell research, offers new therapeutic strategies for high-grade glioma.

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Molecular Therapeutics

Background:

  • High-grade glioma, including glioblastoma multiforme (GBM), has poor patient outcomes due to tumor complexity and resistance.
  • Intratumoral heterogeneity in GBM makes targeted therapies unpredictable and inefficient.
  • The cancer stem cell hypothesis provides insights into GBM's heterogeneity, resistance, and recurrence.

Purpose of the Study:

  • To explore targeting cyclin-dependent kinases (CDKs) in glioblastoma stem cells as a therapeutic strategy.
  • To review the role of cell division characteristics in GBM initiating cells.
  • To discuss the potential of multi-omic approaches for patient stratification in CDK inhibitor therapy.

Main Methods:

  • Review of current research on glioma biology and cancer stem cells.
  • Analysis of the role of cyclin-dependent kinases (CDKs) in GBM initiating cell populations.
  • Examination of multi-omic approaches for therapeutic development.

Main Results:

  • GBM exhibits extreme intratumoral heterogeneity, challenging conventional treatments.
  • Cancer stem cells are implicated in glioma resistance and recurrence.
  • Targeting specific cell division drivers, like CDKs, presents potential therapeutic avenues.

Conclusions:

  • Targeting CDKs in GBM stem cells may offer a novel strategy to improve treatment efficacy.
  • Understanding cell division dynamics in initiating cells is crucial for developing new therapies.
  • Multi-omic data can aid in personalizing CDK inhibitor treatments for glioma patients.

More Related Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K